The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global artificial organs market was valued at US$ 17.4 Billion in 2021.
We expect the global artificial organs market to exhibit a CAGR of 8.8% during 2022-2027.
The increasing instances of organ failures, along with continuous improvements in the existing
healthcare infrastructures, are currently driving the global artificial organs market.
The sudden outbreak of COVID-19 pandemic had led to implementation of stringent lockdown
regulations across several nations resulting in the postponement of elective surgeries to combat the
risk of the coronavirus infection.
Based on the type, the global artificial organs market can be bifurcated into artificial kidney, artificial
heart, artificial pancreas, cochlear implants, and others. Among these, artificial kidneys account for
the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global artificial organs market include Abiomed Inc., Edwards
Lifesciences Corp, HeartWare International, Inc., Cochlear Limited, and Boston Scientific
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at